Gintemetostat

Overview

Gintemetostat (KTX-1001) is an orally active, highly specific NSD2/MMSET histone methyltransferase inhibitor with human NSD2 IC 50 values ranging 0.460-2.17 nM and NSD2 SET domain IC 50 of 2.32 nM and K d values ranging 6.3-70.4 nM.Gintemetostat reduces H 3 K 36 me 2 levels, impairs multiple myeloma cell adhesion and colony formation, enhances cytotoxicity, boosts T-cell activation, and sensitizes resistant multiple myeloma cells to other agents.Gintemetostat can be used for the research of multiple myeloma and relapsed and refractory multiple myeloma.

Application

Products | Products > Disease Areas > Multiple Myeloma | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Histone Methyltransferase | Products > Signaling Pathways > CD44

Product Information

• Catalog No.: HY-154812
• CAS No.: 2604513-16-6
• Molecular Formula: C25H26F4N8O2
• Molecular Weight: 546.52
• Purity: 99.81%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (4.57 mM); Clear solution
• Availability: In-stock

Source

Original product source